Evaluating Alzheimer Disease With Flortaucipir and Florbetapir PET: A Clinical Case Series

Clinical Nuclear Medicine
Olga G JamesTerence Z Wong

Abstract

Early, accurate diagnosis of Alzheimer disease (AD) is essential but remains challenging. Neuropathological hallmarks of AD are β-amyloid neuritic plaques and tau protein neurofibrillary tangles. 18F-Florbetapir is one of several available PET tracers for imaging cortical fibrillary β-amyloid plaques. 18F-Flortaucipir PET was recently approved for evaluating the distribution and density of aggregated neurofibrillary tangles. We present cases of mild cognitive impairment or suspected AD to depict the nuances of flortaucipir distribution and scan interpretation as well as how combined information from amyloid and tau PET may help with differential diagnosis and prognosis.

Related Concepts

Alzheimer's Disease
Cerebral Cortex
Diagnosis
Diagnostic Imaging
Positron-Emission Tomography
Neurofibrillary Degeneration (Morphologic Abnormality)
Tau Proteins
Plaque (Lesion)
Scanning
Neuropathology

Related Feeds

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Related Papers

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Robert H Mach
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Michael D DevousMark A Mintun
© 2021 Meta ULC. All rights reserved